CYP11B2
MOLECULAR TARGETcytochrome P450 family 11 subfamily B member 2
CYP11B2 (cytochrome P450 family 11 subfamily B member 2) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CYP11B2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | abiraterone | 3.66 | 38 |
| 2 | Fadrozole | 3.37 | 28 |
| 3 | metyrapone | 3.30 | 26 |
| 4 | benzylimidazole | 2.89 | 17 |
| 5 | osilodrostat | 2.89 | 17 |
| 6 | dexfadrostat | 2.48 | 11 |
| 7 | s fadrozole | 1.79 | 5 |
| 8 | Etomidate Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or | 1.61 | 4 |
| 9 | Letrozole | 0.69 | 1 |
About CYP11B2 as a Drug Target
CYP11B2 (cytochrome P450 family 11 subfamily B member 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented CYP11B2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CYP11B2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.